Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 142Stomach Neoplasms 104Carcinoma, Non-Small-Cell Lung 87Pancreatic Neoplasms 81Carcinoma, Hepatocellular 74Melanoma 59Esophageal Neoplasms 57Ovarian Neoplasms 50Squamous Cell Carcinoma of Head and Neck 49Parkinson Disease 4, Autosomal Dominant Lewy Body 44Neoplasms 43Carcinoma, Renal Cell 43Triple Negative Breast Neoplasms 39Neoplasm Metastasis 37Lung Neoplasms 36Breast Neoplasms 36Uterine Cervical Neoplasms 35Cholangiocarcinoma 35Esophageal Squamous Cell Carcinoma 33Head and Neck Neoplasms 29Endometrial Neoplasms 29Biliary Tract Neoplasms 26Carcinoma, Transitional Cell 25Urinary Bladder Neoplasms 23Colonic Neoplasms 23Small Cell Lung Carcinoma 20Prostatic Neoplasms 17Liver Neoplasms 17Adenocarcinoma Of Esophagus 15Adenocarcinoma 15

Interventions

trifluridine tipiracil drug combination 1tipiracil 1pembrolizumab 1Trifluridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric and Gastroesophageal Junction Adenocarcinoma × pembrolizumab × Gastrointestinal × Clear all
NCT05508737 2025-07-11

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

Yonsei University

Phase 1/2 Active not recruiting
75 enrolled
Gastrointestinal

Gastric and Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡